Physiomics Plc logo

Physiomics Plc(LSE) PYC

Market Cap£2.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-100%
5 Year-92%
1 Year+14%
1 Month-10%
£0.00
-2.17%
-0.00Today
Physiomics Plc last closing stock price
MetricPriceDate
Last closeGBX 0.482026-10-23
Physiomics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%GBX 0.482026-10-16
1 month-9.52%GBX 0.532026-09-23
3 month+0%GBX 0.482026-07-24
Year to date+66.67%GBX 0.292025-12-31
1 year+14.46%GBX 0.422025-10-23
3 year-68.33%GBX 1.502023-10-24
5 year-92.28%GBX 6.152021-10-22
Since inception-99.79%GBX 2.312004-12-20

Physiomics Plc Financials at a Glance

Market Cap

£2.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£1.73M

Net Income (TTM)

-£1.11M

EPS (TTM)

-£0.00

P/E Ratio

-2.38

Dividend

£0.00

Beta (Volatility)

-0.11 (Low)

Price

£0.00

Volume

200,001

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.01

Estimated Earnings Date

Mar 11, 2027

PYC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Physiomics Plc

Physiomics Plc, founded in 2001 and headquartered in Oxford, UK, specializes in providing consulting services to pharmaceutical companies. The firm focuses on quantitative pharmacology and computational biology, primarily in oncology research, utilizing its proprietary Virtual Tumour predictive software.

Products and Services
  • Consulting services in quantitative pharmacology
  • Computational biology solutions for drug development
  • Proprietary Virtual Tumour predictive software for oncology
Growth Outlook
  • Engagement in personalized medicine technologies is expanding
  • Increasing demand for oncology research solutions drives growth potential
  • Strategic partnerships with pharmaceutical companies enhance market reach
Financial Highlights
  • Recent quarterly revenue of 443,222 GBP shows potential for recovery
  • Cash and cash equivalents reached 418,635 GBP, providing operational stability
  • Current ratio of 2.88 indicates strong liquidity position
Physiomics Plc operates in the biotechnology sector, focusing on innovative solutions for drug development. The company's expertise in quantitative pharmacology and computational biology positions it well within the growing field of personalized medicine. Recent financial data indicates a revenue of 443,222 GBP for the latest quarter, reflecting a potential recovery trajectory. The cash position of 418,635 GBP enhances operational stability, allowing for continued investment in research and development. With a current ratio of 2.88, the company demonstrates a solid liquidity position, which is crucial for navigating the challenges of the biotechnology industry. Overall, Physiomics Plc presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in oncology and personalized medicine.
AI Generated • Oct 19, 2026

Industry

Life Sciences Tools and Services

CEO

Peter Sargent, PhD

Headquarters

Oxford, OXF OX14 4RY, GB

PYC Financials

Key Financial Metrics (TTM)

Gross Margin

-85.12%

Operating Margin

-85.12%

Net Income Margin

-74.06%

Return on Equity

-152.03%

Return on Capital

-152.14%

Return on Assets

-88.39%

Earnings Yield

-42.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£2.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

453.21M

Volume

200.00K

Avg. Volume

3.01M

Financials (TTM)

Gross Profit

-£1.26M

Operating Income

-£1.26M

EBITDA

-£1.24M

Operating Cash Flow

-£1.11M

Capital Expenditure

-£8.36K

Free Cash Flow

-£1.12M

Cash & ST Invst.

£418.64K

Total Debt

£0.00

Physiomics Plc Performance Analysis

Physiomics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30GBP 597,354-28.1%
20242024-06-30GBP 543,250-9.1%
20252025-06-30GBP 784,00544.3%
20262026-06-30GBP 941,22220.1%
Physiomics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3174.5%
Q42025-06-3038.3%
Q22025-12-319.4%
Q42026-06-30-11.0%
Physiomics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30GBP -0.0088.5%
20242024-06-30GBP -0.00-8.2%
20252025-06-30GBP -0.00-62.2%
20262026-06-30GBP -0.0017.6%
Physiomics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-3900.0%
Q42025-06-3099.4%
Q22025-12-31-42.9%
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£443.22K

+135.1%

Gross Profit

-£444.20K

-7.3%

Gross Margin

-1.00%

N/A

Market Cap

£2.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£195.70K

N/A

Employees

11

N/A

Net Income

-£396.03K

+1.8%

EBITDA

-£440.31K

-2.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£418.64K

+119.1%

Total Debt

£0.00

N/A

Accounts Receivable

£342.36K

+126.8%

Inventory

£0.00

+100.0%

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

-100.0%

Return on Assets

-88.39%

N/A

Return on Invested Capital

-1.53%

N/A

Free Cash Flow

-£362.17K

-70.5%

Operating Cash Flow

-£359.74K

-83.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VAL.LValiRx plc
£0.00+0.00%
POLX.LPolarean Imaging plc
£0.00-20.00%
TCF.LTheracryf Plc
£0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About PYC

What is the current price of Physiomics Plc?

Physiomics Plc is trading at £0.00 per share.

What is the 52-week range for Physiomics Plc?

Over the past 52 weeks, Physiomics Plc has traded between £0.00 and £0.01.

How much debt does Physiomics Plc have?

As of the most recent reporting period, Physiomics Plc reported total debt of £0.00.

How much cash does Physiomics Plc have on hand?

Physiomics Plc reported £418.64K in cash and cash equivalents in its most recent financial results.

What is Physiomics Plc’s dividend yield?

Physiomics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.